In8Bio (INAB) Cash from Investing Activities (2021 - 2026)
In8Bio (INAB) posted Cash from Investing Activities of -$9000.0 for Q1 2026, up 72.73% sequentially from -$33000.0 in Q4 2024.
In8Bio (INAB) Cash from Investing Activities (2021 - 2026) Analysis & Trends
In8Bio has reported Cash from Investing Activities for 5 years, with the latest figure at -$9000.0 in Q1 2026.
- Quarterly Cash from Investing Activities changed N/A year-over-year to -$9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9000.0 (up 92.24% YoY) and the FY2024 annual result came in at -$187000.0, up 68.83% from the prior year.
- Cash from Investing Activities improved to -$9000.0 in Q1 2026 per INAB's latest filing, from -$33000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$9000.0 in Q1 2026 and troughed at -$1.8 million in Q3 2022.
- A 4-year average of -$375083.3 and a median of -$80000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 709.62% in 2022, then soared 95.63% in 2023.
- Over 4 years, Cash from Investing Activities stood at -$1.3 million in 2022, then jumped by 94.3% to -$72000.0 in 2023, then surged by 54.17% to -$33000.0 in 2024, then soared by 72.73% to -$9000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$9000.0, -$33000.0, and -$83000.0 for Q1 2026, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | -233,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -233,000.00 |
| Jun 30, 2026 | -233,000.00 |
| Mar 31, 2026 | -9,000.00 |
| Mar 31, 2026 | -9,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Jun 30, 2024 | -83,000.00 |
| Jun 30, 2024 | -83,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Dec 31, 2023 | -72,000.00 |
| Dec 31, 2023 | -72,000.00 |
| Sep 30, 2023 | -77,000.00 |
| Sep 30, 2023 | -77,000.00 |
| Jun 30, 2023 | -22,000.00 |
| Jun 30, 2023 | -22,000.00 |
| Mar 31, 2023 | -429,000.00 |
| Mar 31, 2023 | -429,000.00 |
| Dec 31, 2022 | -1.26 Mn |
| Dec 31, 2022 | -1.26 Mn |